Clinical

Dataset Information

1

TR study of ‘A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (BIGBANG study)"

ABSTRACT: Primary outcome(s): Cancer related genome analysis, gene expression and molecular characterization analysis

DISEASE(S): Colorectal Cancer

PROVIDER: 2647002 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
| S-EPMC7260582 | biostudies-literature
Clinical A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
| 2646999 | ecrin-mdr-crc
Unknown Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
| S-EPMC9271503 | biostudies-literature
Unknown Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
| S-EPMC9271477 | biostudies-literature
Unknown Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
| S-EPMC7370699 | biostudies-literature
Unknown Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
| S-EPMC7004095 | biostudies-literature
Unknown Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines.
| S-EPMC8656772 | biostudies-literature
Unknown Encorafenib plus cetuximab for the treatment of <i>BRAF-V600E</i>-mutated metastatic colorectal cancer.
| S-EPMC9260564 | biostudies-literature
Unknown Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.
| S-EPMC6299465 | biostudies-literature
Unknown Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
| S-EPMC7782586 | biostudies-literature